← Back to Clinical Trials
Recruiting NCT06059313

NCT06059313 Premorbid Personality Profile of Patients With Cognitive and Behavioral Disorders

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06059313
Status Recruiting
Phase
Sponsor Nantes University Hospital
Condition Behavioral Variant of Frontotemporal Disorder (bvFTD)
Study Type OBSERVATIONAL
Enrollment 120 participants
Start Date 2023-12-14
Primary Completion 2026-12-14

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Submission of the NEO-PI-3 questionnaireSubmission of the Interpersonal Reactivity Index questionnaire (IRI)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 120 participants in total. It began in 2023-12-14 with a primary completion date of 2026-12-14.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Damages in frontal area present in neurodegenerative disease (frontotemporal degeneration, frontal variant of Alzheimer disease) and in psychiatric disease (bipolar disorder) can affect behavior and cognition including social cognition. Symptoms vary both quantitatively and qualitatively from disease to another and from person to person. It cannot be completely excluded that in some cases, factors of susceptibility such as premorbid personality traits lead to frontal fragility. The study will assess the relationship between premorbid profile using NEO-PI 3 inventory and cognitive and behavioral/psychobehavioral manifestations in patients with behavioral variant of frontotemporal disorder (bvFTD), phenocopy frontotemporal dementia (phFTD), frontal variant of Alzheimer disease, bipolar disorder characterized with frontal damages.

Eligibility Criteria

Inclusion Criteria : * Patients with behavioral variant of frontotemporal disorder (bvFTD) according to Rascovsky criteria (2011) or patients with phénocopy frontotemporal dementia (phFTD) who fulfill criteria for possible bvFTD and have no imaging abnormalities or patients with frontal variant of Alzheimer disease according to Ossenkopele criteria (2022), or patient with bipolar disorder according to CIM 10 criteria * Score for Mini-mental state examination ≥ 18 * Patient with caregiver who has who has known him/her in the 10 years preceding the disease onset. * Patient and caregiver consents (no opposition) Exclusion Criteria : * Patient with no caregiver * Pregnant or breast feeding women

Contact & Investigator

Central Contact

Claire BOUTOLEAU-BRETONNIERE, PH

✉ claire.boutoleaubretonniere@chu-nantes.fr

📞 33 2 40 16 54 22

Frequently Asked Questions

Who can join the NCT06059313 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Behavioral Variant of Frontotemporal Disorder (bvFTD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06059313 currently recruiting?

Yes, NCT06059313 is actively recruiting participants. Contact the research team at claire.boutoleaubretonniere@chu-nantes.fr for enrollment information.

Where is the NCT06059313 trial being conducted?

This trial is being conducted at Nantes, France.

Who is sponsoring the NCT06059313 clinical trial?

NCT06059313 is sponsored by Nantes University Hospital. The trial plans to enroll 120 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology